Articles By Jack Cush, MD
FDA Approves Ustekinumab for Ulcerative Colitis
Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.
Read Article
Pain Persists Despite TNF Inhibitor Use
Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain.
Read Article
Adalimumab and Pregnancy Outcomes
A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increase
Read Article
Interleukin Targeted Biologics Increase Risks of Infection
A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.
Read Article
RheumNow Podcast – Fight or Switching (DMARDs) (10.18.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Protective Effects of ASA and Vasodilators in Systemic Sclerosis
A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable cardiovascular outcomes.
Read Article
High Dose Statins Increase Odds of Osteoporosis
It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis. A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent.
Read Article
Comorbidity Worsens Axial Spondyloarthritis
Comorbidities are common in patients with axial spondyloarthropathy (axSpA), and a recent study has shown that multimorbidity, the coexistence of 2 or more conditions, is associated with more severe disease than those without comorbidities.
Read Article
One-Third of Psoriatic Arthritis Patients Will Need Joint Surgery
Dannish study has shown that one-third of psoriatic arthritis (PsA) will have joint surgery that that PsA patients have twice the rate of joint surgery when compared with the general population.
Read Article
Warfarin Superior to Xarelto in Antiphospholipid Syndrome
A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.
Read Article
